Featured in "The Most Exciting Science Stories From Israel in 2015"
In a recent review of the most exciting Israeli science stories of 2015, Ruth Schuster of Haaretz notes our groundbreaking work on stem cell-derived hepatocytes and our 'bionic' liver on chip micro-devices. Read more: http://www.haaretz.com/israel-news/science/1.693664 #liver #drugmetabolism #UpcyteTechnologies
European Horizon 2020 program highlights our Nature Biotechnology paper
Gahl Levy's recent Nature Biotechnology paper was highlighted by the European Horizon 2020 program. "An international research team, part-funded by the EU, has set out a new technique for growing human hepatocytes in the laboratory. The research appears in Nature Biotechnology. Read more: http://horizon2020projects.com/sc-health/functional-human-liver-cells-grown-in-the-lab/ #liver #drugmetabolism #UpcyteTechnologies
European Commission reports our liver-on-chip "surpasses animal-based alternatives"
Our collective of liver on chip technology advancement was recently highlighted by the European Commission in its recent review of FP7-funded projects. "The HEMIBIO project has developed a Hepatic Microfluidic Bioreactor mimicking the structure of the human liver. The project team is confident that the new device will eventually help remove the need for testing chemicals on animal subjects". Read more: http://cordis.europa.eu/news/rcn/124243_en.html #liver #drugmetabolism #Up
Haaretz covers Yishai's Hepatology paper
In a recent article in Haaretz newspaper, Ruth Schuster reviews our recent publication that reached the cover of Hepatology. "With all due respect to rat models and extrapolations, to know if a drug does damage to the human liver, it must be tested on a human liver or at least human liver cells (called hepatocytes). The inability to mass-produce viable, functional human liver cells in the lab had been an obstacle that has now been overcome by the team, which reports its work